

Parkinson's Disease and PD Genetic Schedule of Activities (Years 0 - 5)

| Visit Number | | Screening | Baseline (BL) | V02 | V04 | V05 | V06 | R06 | V08 | R08 | V10 | R10 | V12 | Unsched | ^b Transition Activities |
|--|-------------|-----------|---------------|--------|--------------|---------|--------------|---------|--------------|---------|--------------|---------|--------------|---------|------------------------------------|
| Assessment | **Timepoint | -60 days | 0 | 6 mths | 12 (Y1) mths | 18 mths | 24 (Y2) mths | 30 mths | 36 (Y3) mths | 42 mths | 48 (Y4) mths | 54 mths | 60 (Y5) mths | --- | --- |
| Neuropsychological Assessments | | | | | | | | | | | | | | | |
| Benton Judgment of Line Orientation | | | X | | X | | X | | X | | X | | X | | |
| Semantic Fluency (Animals only) | | | X | | X | | X | | X | | X | | X | | |
| Letter Number Sequencing | | | X | | X | | X | | X | | X | | X | | |
| Symbol Digit Modalities Test | | | X | | X | | X | | X | | X | | X | | |
| Trail Making Test (A and B) | | | X | | X | | X | | X | | X | | X | | |
| Modified Boston Naming Test | | | X | | X | | X | | X | | X | | X | | |
| Cognitive Change | | | P | P | P | P | P | | P | | P | | P | | |
| Cognitive Categorization | | | I | | I | | I | | I | | I | | I | | |
| State-Trait Anxiety Inventory for Adults | | | | | | | | | | | | | | | |
| | | | P | | P | | P | | P | | P | | P | | |
| Geriatric Depression Scale | | | | | | | | | | | | | | | |
| | | | P | | P | | P | | P | | P | | P | | |
| QUIP | | | | | | | | | | | | | | | |
| | | | P | | P | | P | | P | | P | | P | | |
| Clinical and Biological Samples | | | | | | | | | | | | | | | |
| Clinical Lab blood sample | | X | | | X | | X | | X | | X | | X | X | |
| Research samples (blood + urine) | | | X | X | X | X | X | | X | | X | | X | | |
| Lumbar puncture | | | X | | X | | X | | X | | X | | X | | |
| Skin biopsy | | | X | | | | X | | | | X | | | | |
| Imaging Activities | | | | | | | | | | | | | | | |
| DaTscan Imaging Screening Intake | | X | | | | | | | | | | | | | |
| Pregnancy Test (prior to Datscan injection), if applicable | | X | | | X | | X | | | | X | | | | |
| DaTscan Imaging | | X | | | X | | X | | | | X | | | | |
| MRI | | | X | | X | | X | | | | X | | | | |
| Safety and General Health | | | | | | | | | | | | | | | |
| #Adverse Events | | X | X | | X | | X | | X | | X | | X | X | |
| Adverse Event Telephone Assessment | | X | X | | X | | X | | X | | X | | X | | |
| Current Medical Conditions Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| Concomitant Medication Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| LEDD Concomitant Medication Log | | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| Surgery for PD Log | | | As Needed | | | | | | | | | | | | |
| Report of Pregnancy | | | As Needed | | | | | | | | | | | | |

I = Investigator completed assessment

P = Participant completed assessment

X = Investigator or Coordinator completed assessment (or as otherwise delegated)

R0X Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability will not be assessed for Remote visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all 1.0 participants transitioning into 2.0 at first 2.0 visit only

**Window of +45 days either side of Target Visit Date

#Adverse events collected only day of and 7-10 days post DaTscan, LP and skin biopsy per protocol.

Parkinson's Disease and PD Genetic Schedule of Activities (Years 6-13)

| Visit Number | R12 | V13 | R13 | V14 | R14 | V15 | R15 | V16 | R16 | V17 | R17 | V18 | R18 | V19 | R19 | V20 | Unsched | ^b Transition Activities | |
|--|-------------|---------|--------------|---------|--------------|---------|--------------|----------|---------------|----------|----------------|----------|----------------|----------|----------------|----------|----------------|------------------------------------|-----|
| Assessment | **Timepoint | 66 mths | 72 (Y6) mths | 78 mths | 84 (Y7) mths | 90 mths | 96 (Y8) mths | 102 mths | 108 (Y9) mths | 114 mths | 120 (Y10) mths | 126 mths | 132 (Y11) mths | 138 mths | 144 (Y12) mths | 150 mths | 156 (Y13) mths | --- | --- |
| Neuropsychological Assessments | | | | | | | | | | | | | | | | | | | |
| State-Trait Anxiety Inventory for Adults | | P | | P | | P | | P | | P | | P | | P | | P | | | |
| Geriatric Depression Scale | | P | | P | | P | | P | | P | | P | | P | | P | | | |
| QUIP | | P | | P | | P | | P | | P | | P | | P | | P | | | |
| Clinical and Biological Samples | | | | | | | | | | | | | | | | | | | |
| Clinical Lab blood sample | | X | | X | | X | | X | | X | | X | | X | | X | X | | |
| Research samples (blood + urine) | | X | | X | | X | | X | | X | | X | | X | | X | | | |
| Lumbar puncture | | | | X | | | | X | | | | X | | | | X | | | |
| Skin biopsy | | | | X | | | | X | | | | X | | | | X | | | |
| Safety and General Health | | | | | | | | | | | | | | | | | | | |
| #Adverse Events | | | | X | | | | X | | | | X | | | | X | X | | |
| Adverse Event Telephone Assessment | | | | X | | | | X | | | | X | | | | X | | | |
| Current Medical Conditions Review | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| Concomitant Medication Review | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| LEDD Concomitant Medication Log | As Needed | | | | | | | | | | | | | | | | | | |
| Surgery for PD Log | As Needed | | | | | | | | | | | | | | | | | | |
| Report of Pregnancy | As Needed | | | | | | | | | | | | | | | | | | |

I = Investigator completed assessment

P = Participant completed assessment

ROX Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability will not be assessed for Remote visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all 1.0 participants transitioning into 2.0 at first 2.0 visit only

**Window of +45 days either side of Target Visit Date

#Adverse events collected only day of and 7-10 days post LP and skin biopsy per protocol.

Healthy Control Schedule of Activities (Years 0 - 5)

| Visit Number | Screening | Baseline (BL) | V02 | V04 | V05 | V06 | R06 | V08 | R08 | V10 | R10 | V12 | Unsched | ^b Transition Activities | |
|--|-------------|---------------|-----|--------|--------------|---------|--------------|---------|--------------|---------|--------------|---------|---------|------------------------------------|-----------|
| Assessment | **Timepoint | -60 days | 0 | 6 mths | 12 (Y1) mths | 18 mths | 24 (Y2) mths | 30 mths | 36 (Y3) mths | 42 mths | 48 (Y4) mths | 54 mths | 60 (Y5) | -- | -- |
| Semantic Fluency (Animals only) | | | X | | X | | X | | X | | X | | X | | |
| Letter Number Sequencing | | | X | | X | | X | | X | | X | | X | | |
| Symbol Digit Modalities Test | | | X | | X | | X | | X | | X | | X | | |
| Trail Making Test (A and B) | | | X | | X | | X | | X | | X | | X | | |
| Modified Boston Naming Test | | | X | | X | | X | | X | | X | | X | | |
| Cognitive Change | | | P | P | P | P | P | | P | | P | | P | | |
| Cognitive Categorization | | | I | | I | | I | | I | | I | | I | | |
| Neuropsychological Assessments | | | | | | | | | | | | | | | |
| State-Trait Anxiety Inventory for Adults | | | P | | P | | P | | P | | P | | P | | |
| Geriatric Depression Scale | | | P | | P | | P | | P | | P | | P | | |
| QUIP | | | P | | P | | P | | P | | P | | P | | |
| Clinical and Biological Samples | | | | | | | | | | | | | | | |
| Clinical Lab blood sample | | X | | | X | | X | | X | | X | | X | X | |
| Research samples (blood + urine) | | | X | X | X | X | X | | X | | X | | X | | |
| Lumbar puncture | | | X | | X | | X | | X | | X | | X | | |
| Skin biopsy | | | X | | | | X | | | | X | | | | |
| Imaging Activities | | | | | | | | | | | | | | | |
| DaTscan Imaging Screening Intake | | X | | | | | | | | | | | | | |
| Pregnancy Test (prior to DaTscan injection), if applicable | | X | | | | | | | | | | | | | |
| DaTscan Imaging | | X | | | | | | | | | | | | | |
| MRI | | | X | | | | | | | | | | | | |
| Safety and General Health | | | | | | | | | | | | | | | |
| # Adverse Events | | X | X | | X | | X | | X | | X | | X | X | |
| Adverse Event Telephone Assessment | | X | X | | X | | X | | X | | X | | X | | |
| Current Medical Conditions Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| Concomitant Medication Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| Report of Pregnancy | | | | | | | | | | | | | | | As Needed |

I = Investigator completed assessment

P = Participant completed assessment

X = Investigator or Coordinator completed assessment (or as otherwise delegated)

R0X Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability will not be assessed for Remote visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all 1.0 participants transitioning into 2.0 at first 2.0 visit only

**Window of +45 days either side of Target Visit Date

#Adverse events collected only day of and 7-10 days post DaTscan, LP and skin biopsy per protocol.

Healthy Control Schedule of Activities (Years 6-13)

| Visit Number | | R12 | V13 | R13 | V14 | R14 | V15 | R15 | V16 | R16 | V17 | R17 | V18 | R18 | V19 | R19 | V20 | Unsched | ^b Transition Activities |
|--|-------------|-----------|---------|---------|---------|---------|---------|----------|----------|---------|-----------|----------|-----------|----------|-----------|----------|-----------|---------|------------------------------------|
| Assessment | **Timepoint | 66 mths | 72 (Y6) | 78 mths | 84 (Y7) | 90 mths | 96 (Y8) | 102 mths | 108 (Y9) | 114 mth | 120 (Y10) | 126 mths | 132 (Y11) | 138 mths | 144 (Y12) | 150 mths | 156 (Y13) | -- | -- |
| Geriatric Depression Scale | | | P | | P | | P | | P | | P | | P | | P | | P | | |
| QUIP | | | P | | P | | P | | P | | P | | P | | P | | P | | |
| Clinical and Biological Samples | | | | | | | | | | | | | | | | | | | |
| Clinical Lab blood sample | | | X | | X | | X | | X | | X | | X | | X | | X | X | |
| Research samples (blood + urine) | | | X | | X | | X | | X | | X | | X | | X | | X | | |
| Lumbar puncture | | | | | X | | | | X | | | | X | | | | X | | |
| Skin biopsy | | | | | X | | | | X | | | | X | | | | X | | |
| Safety and General Health | | | | | | | | | | | | | | | | | | | |
| # Adverse Events | | | | | X | | | | X | | | | X | | | | X | X | |
| Adverse Event Telephone Assessment | | | | | X | | | | X | | | | X | | | | X | | |
| Current Medical Conditions Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Concomitant Medication Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X |
| Report of Pregnancy | | As Needed | | | | | | | | | | | | | | | | | |

I = Investigator completed assessment

P = Participant completed assessment

R0X Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability will not be assessed for Remote visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all 1.0 participants transitioning into 2.0 at first 2.0 visit only

**Window of +45 days either side of Target Visit Date

#Adverse events collected only day of and 7-10 days post LP and skin biopsy per protocol.

Prodromal Schedule of Activities (Years 0 - 5)

| Visit Number | | SC (DAT) | BL (Clinic) | R01 | V04 | R04 | V06 | R06 | V08 | R08 | V10 | R10 | V12 | Unsched | ^b Transition Activities |
|--|-------------|----------|-------------|-----------|--------------|---------|--------------|---------|--------------|---------|--------------|---------|--------------|---------|------------------------------------|
| Assessment | **Timepoint | -60 days | 0 | 6 mths | 12 (Y1) mths | 18 mths | 24 (Y2) mths | 30 mths | 36 (Y3) mths | 42 mths | 48 (Y4) mths | 54 mths | 60 (Y5) mths | -- | -- |
| Lexical Fluency | | | X | | X | | X | | X | | X | | X | | |
| Hopkins Verbal Learning Test-Revised | | | X | | X | | X | | X | | X | | X | | |
| Benton Judgment of Line Orientation | | | X | | X | | X | | X | | X | | X | | |
| Semantic Fluency (Animals only) | | | X | | X | | X | | X | | X | | X | | |
| Letter Number Sequencing | | | X | | X | | X | | X | | X | | X | | |
| Symbol Digit Modalities Test | | | X | | X | | X | | X | | X | | X | | |
| Trail Making Test (A and B) | | | X | | X | | X | | X | | X | | X | | |
| Modified Boston Naming Test | | | X | | X | | X | | X | | X | | X | | |
| Cognitive Change | | | P | | P | | P | | P | | P | | P | | |
| Cognitive Categorization | | | I | | I | | I | | I | | I | | I | | |
| Neuropsychological Assessments | | | | | | | | | | | | | | | |
| State-Trait Anxiety Inventory for Adults | | | P | | P | | P | | P | | P | | P | | |
| Geriatric Depression Scale | | | P | | P | | P | | P | | P | | P | | |
| QUIP | | | P | | P | | P | | P | | P | | P | | |
| Clinical and Biological Samples | | | | | | | | | | | | | | | |
| Clinical Lab blood sample | | | X | | X | | X | | X | | X | | X | X | |
| Research samples (blood + urine) | | | X | | X | | X | | X | | X | | X | | |
| Lumbar puncture | | | X | | X | | X | | X | | X | | X | | |
| Skin biopsy | | | X | | | | X | | | | X | | | | |
| Imaging Activities | | | | | | | | | | | | | | | |
| DaTscan Imaging Screening Intake | | X | | | | | | | | | | | | | |
| Pregnancy Test (prior to DaTscan injection), if applicable | | X | | | X | | X | | | | X | | | | |
| DaTscan Imaging | | X | | | X | | X | | | | X | | | | |
| MRI | | | X | | X | | X | | | | X | | | | |
| Safety and General Health | | | | | | | | | | | | | | | |
| # Adverse Events | | X | X | | X | | X | | X | | X | | X | X | |
| Adverse Event Telephone Assessment | | X | X | | X | | X | | X | | X | | X | | |
| Current Medical Conditions Review | | | X | X | X | X | X | X | X | X | X | X | X | X | |
| Concomitant Medication Review | | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| LEDD Concomitant Medication Log | | | | As Needed | | | | | | | | | | | |
| Surgery for PD Log | | | | As Needed | | | | | | | | | | | |
| Report of Pregnancy | | | | As Needed | | | | | | | | | | | |

I = Investigator completed assessment

P = Participant completed assessment

X = Investigator or Coordinator completed assessment (or as otherwise delegated)

R0X Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability will not be assessed for Remote visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all 1.0 participants transitioning into 2.0 at first 2.0 visit only

**Window of +45 days either side of Target Visit Date

#Adverse events collected only day of and 7-10 days post DaTscan, LP and skin biopsy per protocol.

Prodromal Schedule of Activities (Years 6-13)

| Visit Number | R12 | V13 | R13 | V14 | R14 | V15 | R15 | V16 | R16 | V17 | R17 | V18 | R18 | V19 | R19 | V20 | Unsched | ^b Transition Activities | |
|--|-------------|-----------|--------------|---------|--------------|---------|--------------|----------|---------------|----------|----------------|----------|----------------|----------|----------------|----------|----------------|------------------------------------|----|
| Assessment | **Timepoint | 66 mths | 72 (Y6) mths | 78 mths | 84 (Y7) mths | 90 mths | 96 (Y8) mths | 102 mths | 108 (Y9) mths | 114 mths | 120 (Y10) mths | 126 mths | 132 (Y11) mths | 138 mths | 144 (Y12) mths | 150 mths | 156 (Y13) mths | -- | -- |
| Neuropsychological Assessments | | | | | | | | | | | | | | | | | | | |
| State-Trait Anxiety Inventory for Adults | | P | | P | | P | | P | | P | | P | | P | | P | | | |
| Geriatric Depression Scale | | P | | P | | P | | P | | P | | P | | P | | P | | | |
| QUIP | | P | | P | | P | | P | | P | | P | | P | | P | | | |
| Clinical and Biological Samples | | | | | | | | | | | | | | | | | | | |
| Clinical Lab blood sample | | X | | X | | X | | X | | X | | X | | X | | X | | X | |
| Research samples (blood + urine) | | X | | X | | X | | X | | X | | X | | X | | X | | | |
| Lumbar puncture | | | | X | | | | X | | | | X | | | | X | | | |
| Skin biopsy | | | | X | | | | X | | | | X | | | | X | | | |
| Safety and General Health | | | | | | | | | | | | | | | | | | | |
| #Adverse Events | | | | X | | | | X | | | | X | | | | X | | X | |
| Adverse Event Telephone Assessment | | | | X | | | | X | | | | X | | | | X | | | |
| Current Medical Conditions Review | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| Concomitant Medication Review | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| LEDD Concomitant Medication Log | | As Needed | | | | | | | | | | | | | | | | | |
| Surgery for PD Log | | As Needed | | | | | | | | | | | | | | | | | |
| Report of Pregnancy | | As Needed | | | | | | | | | | | | | | | | | |

I = Investigator completed assessment

P = Participant completed assessment

ROX Visits are conducted remotely (e.g., video, audio)

a = rigidity and postural stability will not be assessed for Remote visits; Part III and Hoehn & Yahr not done if phone/audio only

b = Transition Activities completed for all 1.0 participants transitioning into 2.0 at first 2.0 visit only

**Window of +45 days either side of Target Visit Date

#Adverse events collected only day of and 7-10 days post LP and skin biopsy per protocol.